August 6, 2009 - Orexo AB today announces that its partner, UK-based international specialty pharmaceutical company ProStrakan Group plc, has submitted the New Drug Application (NDA) for Abstral™ (rapinyl)(for the treatment of breakthrough cancer pain in opioid-tolerant patients) to the US FDA.
the details can be read here.
No comments:
Post a Comment